Marksans Pharma Limited (MARKSANS.NS)
INR 223.25
(1.76%)
INR 223.25
(1.76%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 7.71 Billion INR | -17.13% |
| 2022 | 9.3 Billion INR | 27.14% |
| 2021 | 7.32 Billion INR | -2.36% |
| 2020 | 7.49 Billion INR | 33.65% |
| 2019 | 5.6 Billion INR | 19.4% |
| 2018 | 4.69 Billion INR | 28.9% |
| 2017 | 3.64 Billion INR | 23.5% |
| 2016 | 2.95 Billion INR | -23.07% |
| 2015 | 3.83 Billion INR | 9.22% |
| 2014 | 3.51 Billion INR | 34.03% |
| 2013 | 2.62 Billion INR | 41.23% |
| 2012 | 1.85 Billion INR | 30.1% |
| 2011 | 1.42 Billion INR | 110.4% |
| 2010 | 677.85 Million INR | 3.97% |
| 2009 | 651.94 Million INR | -11.26% |
| 2008 | 734.69 Million INR | 15.23% |
| 2007 | 637.59 Million INR | 40.89% |
| 2006 | 452.53 Million INR | -33.7% |
| 2005 | 682.53 Million INR | 6.31% |
| 2004 | 642.01 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.27 Billion INR | 20.34% |
| 2023 Q2 | 2.78 Billion INR | 8.26% |
| 2023 Q3 | 3.13 Billion INR | 12.49% |
| 2023 Q1 | 2.57 Billion INR | 6.25% |
| 2023 FY | 7.71 Billion INR | -17.13% |
| 2023 Q4 | 1.89 Billion INR | -39.55% |
| 2022 Q4 | 2.42 Billion INR | 0.74% |
| 2022 Q2 | 2.29 Billion INR | 4.75% |
| 2022 FY | 9.3 Billion INR | 27.14% |
| 2022 Q1 | 2.18 Billion INR | 33.08% |
| 2022 Q3 | 2.4 Billion INR | 4.79% |
| 2021 Q3 | 1.95 Billion INR | 5.0% |
| 2021 Q1 | 1.86 Billion INR | 25.71% |
| 2021 FY | 7.32 Billion INR | -2.36% |
| 2021 Q2 | 1.85 Billion INR | -0.45% |
| 2021 Q4 | 1.64 Billion INR | -15.68% |
| 2020 Q3 | 2.16 Billion INR | 12.52% |
| 2020 Q2 | 1.92 Billion INR | 0.62% |
| 2020 Q1 | 1.91 Billion INR | 20.34% |
| 2020 FY | 7.49 Billion INR | 33.65% |
| 2020 Q4 | 1.48 Billion INR | -31.55% |
| 2019 Q3 | 1.47 Billion INR | 19.2% |
| 2019 Q1 | 1.2 Billion INR | 30.66% |
| 2019 Q4 | 1.59 Billion INR | 7.93% |
| 2019 Q2 | 1.23 Billion INR | 2.48% |
| 2019 FY | 5.6 Billion INR | 19.4% |
| 2018 Q4 | 924.22 Million INR | -23.09% |
| 2018 Q3 | 1.2 Billion INR | -12.85% |
| 2018 Q2 | 1.37 Billion INR | 15.52% |
| 2018 FY | 4.69 Billion INR | 28.9% |
| 2018 Q1 | 1.19 Billion INR | 75.1% |
| 2017 FY | 3.64 Billion INR | 23.5% |
| 2017 Q4 | 681.68 Million INR | -34.44% |
| 2017 Q3 | 1.03 Billion INR | 6.51% |
| 2017 Q2 | 976.27 Million INR | 3.06% |
| 2017 Q1 | 947.31 Million INR | 79.2% |
| 2016 Q3 | 949.67 Million INR | 34.99% |
| 2016 Q2 | 703.52 Million INR | -8.59% |
| 2016 Q1 | 769.64 Million INR | 17.57% |
| 2016 Q4 | 528.63 Million INR | -44.33% |
| 2016 FY | 2.95 Billion INR | -23.07% |
| 2015 Q2 | 1.19 Billion INR | 28.71% |
| 2015 FY | 3.83 Billion INR | 9.22% |
| 2015 Q3 | 1.06 Billion INR | -10.82% |
| 2015 Q4 | 654.62 Million INR | -38.43% |
| 2015 Q1 | 926.29 Million INR | 15.47% |
| 2014 Q1 | 829.29 Million INR | 51.61% |
| 2014 Q4 | 802.16 Million INR | -16.35% |
| 2014 Q3 | 958.91 Million INR | 3.99% |
| 2014 FY | 3.51 Billion INR | 34.03% |
| 2014 Q2 | 922.15 Million INR | 11.2% |
| 2013 Q4 | 546.98 Million INR | -25.47% |
| 2013 Q3 | 733.92 Million INR | 6.2% |
| 2013 Q1 | 621.23 Million INR | 14.48% |
| 2013 FY | 2.62 Billion INR | 41.23% |
| 2013 Q2 | 691.07 Million INR | 11.24% |
| 2012 Q1 | 404.28 Million INR | 0.0% |
| 2012 FY | 1.85 Billion INR | 30.1% |
| 2012 Q4 | 542.64 Million INR | 19.84% |
| 2012 Q3 | 452.8 Million INR | -0.67% |
| 2012 Q2 | 455.85 Million INR | 12.76% |
| 2011 FY | 1.42 Billion INR | 110.4% |
| 2010 FY | 677.85 Million INR | 3.97% |
| 2009 FY | 651.94 Million INR | -11.26% |
| 2008 FY | 734.69 Million INR | 15.23% |
| 2007 FY | 637.59 Million INR | 40.89% |
| 2006 FY | 452.53 Million INR | -33.7% |
| 2005 FY | 682.53 Million INR | 6.31% |
| 2004 FY | 642.01 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Abbott India Limited | 26.16 Billion INR | 70.519% |
| Cipla Limited | 161.81 Billion INR | 95.233% |
| Gland Pharma Limited | 16.6 Billion INR | 53.537% |
| GlaxoSmithKline Pharmaceuticals Limited | 12.82 Billion INR | 39.831% |
| Kopran Limited | 2.12 Billion INR | -262.739% |
| NGL Fine-Chem Limited | 1.23 Billion INR | -525.895% |
| Pfizer Limited | 9.9 Billion INR | 22.124% |
| Sanofi India Limited | 16.32 Billion INR | 52.749% |
| SMS Pharmaceuticals Limited | 2.1 Billion INR | -265.693% |
| TTK Healthcare Limited | 2.68 Billion INR | -187.137% |